Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.
临床前和临床证据表明氯胺酮具有快速抗抑郁作用。使用 AMPA 抑制剂预处理的研究表明，增强 AMPA 通透性对于氯胺酮的作用至关重要，包括增加基础和诱发γ波的功率。本研究旨在复制先前的研究结果，即在 31 名抑郁患者和 25 名健康对照者中，氯胺酮反应者与非反应者在 230 分钟和第 1 天对躯体感觉刺激的γ反应增加。在抑郁的氯胺酮反应者与非反应者之间观察到峰值γ功率的显著差异。这些结果表明 AMPA 通透性参与了氯胺酮的抗抑郁作用机制。
